Focused On-demand Library for Signal transducer CD24

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

P25063

UPID:

CD24_HUMAN

Alternative names:

Small cell lung carcinoma cluster 4 antigen

Alternative UPACC:

P25063; A0A087WYI6; B6EC88; Q16257; Q53XS0; R4I4T5

Background:

Signal transducer CD24, also known as Small cell lung carcinoma cluster 4 antigen, plays a crucial role in cell differentiation and immune response modulation. Its interaction with lectin-like ligands and subsequent signaling through GPI-anchor derived second messengers, significantly influences B-cell activation, proliferation, and the suppression of immune responses to danger-associated molecular patterns (DAMPs) such as HMGB1, HSP70, and HSP90.

Therapeutic significance:

Given its involvement in autoimmune diseases like Multiple sclerosis, where it is implicated in the autoimmune attack on the myelin sheath, understanding the role of CD24 could unveil novel therapeutic strategies aimed at modulating immune responses and promoting myelin sheath repair.